Imperagen

Imperagen, a Manchester-based techbio company leveraging AI and quantum physics for enzyme engineering, has successfully secured £5 million in a seed funding round. This investment was led by PXN Ventures, with additional participation from existing investors IQ Capital and Northern Gritstone, bringing Imperagen's total funding to £8.5 million.

Summary of transaction details:

• Value: £5,000,000
• Sector: Healthcare & Biotech
• Advisor: Not specified
• Key Entities: Target: Imperagen; Lead Investor: PXN Ventures; Participating Investors: IQ Capital, Northern Gritstone
• Location: Manchester, UK

Note: This funding round is intended to significantly accelerate Imperagen's research and development efforts, supporting the expansion of its innovative enzyme engineering platform.